SCHEMBL17633666

SCHEMBL17633666

COc1ccc2c(c1)NC(=O)C(c1ccc(C(F)(F)F)cc1)O2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.43
CA2 P00918 2/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
BRD4 O60885 1/20 0.40
MAOB P27338 1/20 0.40
HSD17B10 Q99714 2/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
GSK3B P49841 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
PIK3CA P42336 1/20 0.37
EPHX2 P34913 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17634129 0.91 BRD4 (0.46) CYP2C19LMNACA2NPC1RAB9A
SCHEMBL17634259 0.88 ABL1 (0.43) BRD4
SCHEMBL6981242 0.84 ABCB1 (0.49) CYP2C19LMNACA2NPC1RAB9A
SCHEMBL17634285 0.83 BRD4 (0.40) CA2BRD4GSK3BMEN1KMT2A
SCHEMBL17633653 0.81 BRD4 (0.43) BRD4HSD17B10PGR
SCHEMBL17634230 0.81 BRD4 (0.39) CA2BRD4CCNB2CDK1CCNB1
SCHEMBL17634188 0.79 BRD4 (0.44) CYP2C19LMNABRD4PGR
SCHEMBL17634084 0.78 PARP1 (0.49) CA2BRD4HSD17B10GSK3BMEN1
SCHEMBL17634240 0.76 ABL1 (0.42)
SCHEMBL7122774 0.76 PARP1 (0.53) CA2NPC1RAB9ABRD4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197900-B1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME (US) 2020-02-12 EP disclosed
US-9969752-B2 Inhibitors of HIF prolyl hydroxylase MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2017-08-17 US disclosed
EP-3197900-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE Merck Sharp & Dohme Corp. (US) 2017-08-02 EP disclosed
WO-2016049099-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed
WO-2016045127-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233412-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE HIF1AN, HIF1A, EGLN2 CYP2C19 1244/4885LMNA 3687/4885CA2 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.